PDF herunterladen
Semin intervent Radiol 2024; 41(01): 079-083
DOI: 10.1055/s-0043-1778656
Back to Basics

Embolic Agents: Sclerotherapy

Autoren

  • Christina Lim

    1   Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, Creighton University School of Medicine, Baltimore, Maryland

  • Sean Lee

    2   Touro College of Osteopathic Medicine, New York City, New York

  • Abheek Ghosh

    3   Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland

  • Brian Funaki

    4   Division of Vascular and Interventional Radiology, University of Chicago Medicine, Chicago, Illinois
Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

History of Sclerosants

The first use of injection sclerotherapy to occlude a vessel was performed by Daniel Zollikofer in 1682. He reportedly injected an acid into a vein to promote thrombosis. This initial attempt led to further development of the procedure and the sclerosing agent. One of the earliest successes in the administration of a sclerosant occurred in 1853 at the Academy of Medicine in Paris where Professors Joseph Pierre Pétrequin and Soquet developed an iodine-tannin solution that produced fewer complications when injected. However, a redefinition of sclerotherapy's goal in 1894 prompted a new direction for sclerosing agents when Delore, a surgeon, proposed to a surgical congress in Lyon that a sclerosant should harden rather than thrombose the vessel. This concept garnered widespread recognition that continued into the 1900s. Paul Linser, a professor of dermatology in Tubingen, used mercury perchlorate solutions to treat varicosities after observing that mercury in syphilis treatments caused sclerosis of arm veins. However, mercurial preparations quickly fell out of favor due to their high toxicity; thus, alternative agents such as iron perchloride, alcohol, and sodium salicylate were explored.[1] Most sclerosants were associated with high toxicity to excessive causticity. A breakthrough occurred in 1946 when Leopold Reiner, a German surgeon, introduced sodium tetradecyl sulfate (STS), a detergent, as a safe and effective sclerosant. Subsequently, another detergent, polidocanol (POL), initially developed as a local anesthetic but abandoned due to its tendency to induce thrombosis, gained renewed purpose as a sclerosant by Otto Henschel, scientific director of Kreussler Pharma in Germany. As the range of sclerosants expanded and their properties were refined, injection sclerotherapy surpassed surgery in popularity for the treatment of diseased veins in the 1960s.[2]



Publikationsverlauf

Artikel online veröffentlicht:
14. März 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA